Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2017 Oct 2:22:75-77.
doi: 10.1016/j.gore.2017.09.015. eCollection 2017 Nov.

Norethindrone substituted for megestrol in the treatment of metastatic endometrial carcinoma: Three cases

William L Read  1 , Sumita Trivedi  2 , Felicia Williams  1
Affiliations
Case Reports

Norethindrone substituted for megestrol in the treatment of metastatic endometrial carcinoma: Three cases

William L Read et al. Gynecol Oncol Rep. .

Abstract

•Progestins can produce clinical benefit in a subset of women with metastatic endometrial cancer.•Corticosteroid-related effects of megestrol can cause morbidity over the long term.•Norethindrone is a progestin without corticosteroid side effects.•A switch from megestrol to norethindrone decreased toxicity with continued benefit.•A clinical trial of norethindrone for this population of patients would be welcome.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Representative lung metastases are seen to first cavitate and then regress completely during endocrine therapy.
Fig. 2
Fig. 2
Large metastatic lesions in the lung are seen to regress almost completely during megestrol followed by norethindrone therapy.
See this image and copyright information in PMC

References

    1. Chandra V., Kim J.J., Benbrook D.M., Dwivedi A., Rai R. Therapeutic options for management of endometrial hyperplasia. J. Gynecol. Oncol. 2016;27(1):e8. https://doi.org/10.3802/jgo.2016.27.e8 Epub 2015/10/16. (PubMed PMID: 26463434; PubMed Central PMCID: PMCPMC4695458) - DOI - PMC - PubMed
    1. Chwalisz K., Surrey E., Stanczyk F.Z. The hormonal profile of norethindrone acetate: rationale for add-back therapy with gonadotropin-releasing hormone agonists in women with endometriosis. Reprod. Sci. 2012;19(6):563–571. https://doi.org/10.1177/1933719112438061 Epub 2012/03/30. (PubMed PMID: 22457429) - DOI - PubMed
    1. Derham R.J., Buchan P.C. Haemorheological consequences of oestrogen and progestogen therapy. Eur. J. Obstet. Gynecol. Reprod. Biol. 1989;32(2):109–114. (Epub 1989/08/01. PubMed PMID: 2673883) - PubMed
    1. Dev R., Del Fabbro E., Bruera E. Association between megestrol acetate treatment and symptomatic adrenal insufficiency with hypogonadism in male patients with cancer. Cancer. 2007;110(6):1173–1177. - PubMed
    1. Elit L., Hirte H. Novel strategies for systemic treatment of endometrial cancer. Expert Opin. Investig. Drugs. 2000;9(12):2831–2853. - PubMed

Publication types

LinkOut - more resources